In January 2026, the Consumer Financial Protection Bureau (CFPB) released a report highlighting the increasing use – and potential pitfalls – of medical credit cards and financing plans. These products, once largely limited to elective procedures, are now frequently offered for basic medical treatment and emergency healthcare, according to the CFPB.
Medical credit cards are designed to finance healthcare expenses, but many carry a deferred interest feature that can prove costly for patients. This feature retroactively applies interest from the date of purchase if a balance isn’t paid in full by the end of a promotional period, even if payments were made on time. WalletHub reported on January 29, 2026, that these cards typically only work for specific healthcare expenses and with participating providers, limiting their usability.
Healthcare professionals often present these cards as a payment option directly to patients, sometimes during moments of significant stress, as noted in the CFPB report. Issuers include specialized credit card companies like Comenity Bank, and Synchrony. The CFPB’s scrutiny reflects concerns about high interest rates and potential conflicts of interest when healthcare providers steer patients toward these financing options.
Alternatives to medical credit cards are gaining traction. Cherry Payment Plans, for example, ties approvals directly to the healthcare practice, restricting fund usage to the specific treatment plan. CardRates.com suggests that open-loop credit cards with 0% introductory APRs may be a better option for those who qualify, avoiding the deferred interest traps common with medical-specific cards.
While medical credit cards can help patients access needed care, their limitations – including restricted usage and the risk of deferred interest – are prompting increased examination of financing options. The CFPB report does not indicate any forthcoming regulations, but the agency’s attention signals a potential shift in oversight of the medical financing industry.
